Decitabine plus busulfan–cyclophosphamide versus busulfan–cyclophosphamide myeloablative conditioning before allogeneic haematopoietic stem cell transplantation for reducing risk of relapse in adult KMT2A‑rearranged leukaemia in China: an open-label, multicentre, randomised phase 3 trial

The Lancet Haematology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles